Covalently linked antigen-antibody conjugates
Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
1. An isolated antibody that binds to biotin, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 57; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 58; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 59; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:62; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 63.
2. The antibody of claim 1 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 60 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 64.
3. An isolated antibody that binds to theophylline, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 89; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 90; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 91; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 93; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:94; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 95.
4. The antibody of claim 3 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 96.
5. An isolated antibody that binds to fluorescein, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 105; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 106; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 107; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 109; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:110; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 111.
6. The antibody of claim 5 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 108 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 112.
7. An isolated antibody that binds to digoxigenin, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 25; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 26; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 27; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 31.
8. The antibody of claim 7 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 28 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 32.
9. The antibody of claim 1 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to biotin and a second binding site that specifically binds to a cell surface marker.
10. The antibody of claim 1 , wherein the antibody is humanized.
11. The antibody of claim 3 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to theophylline and a second binding site that specifically binds to a cell surface marker.
12. The antibody of claim 3 , wherein the antibody is humanized.
13. The antibody of claim 5 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to fluorescein and a second binding site that specifically binds to a cell surface marker.
14. The antibody of claim 5 , wherein the antibody is humanized.
15. The antibody of claim 7 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to digoxigenin and a second binding site that specifically binds to a cell surface marker.
16. The antibody of claim 7 , wherein the antibody is humanized.